CD274 and neoplasm: A multi-biomarker approach that integrates PD-L1 expression, HPV status, and TMB—alongside emerging factors such as immune gene expression profiling, tumor microenvironment characteristics, and microbiome composition—may provide a more comprehensive framework for patient selection.